Pimicotinib delivers lasting tumor responses and sustained symptom relief in TGCT patients
Global Phase 3 MANEUVER study highlights ongoing benefits and consistent safety profile
Global Phase 3 MANEUVER study highlights ongoing benefits and consistent safety profile
The expansion underscores Merck’s commitment to invest more than $70 billion in U.S. research, development and capital projects
Results from the Phase 2 PHAROS trial potentially establish new benchmark with targeted combination therapies for this patient population
Contera Pharma will receive an upfront payment and full research funding for each target under investigation
This partnership marks a significant step in strengthening Healthium’s position in the cardiac care segment
Acquisition aims to strengthen Merck's downstream process offering of advanced filtration and chromatography solutions
The new plant will manufacture high-quality Type I borosilicate glass tubing
The study met its primary endpoint, demonstrating a highly statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to chemotherapy
Subscribe To Our Newsletter & Stay Updated